Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610047 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness
A Phase 2 study of Influenza and Influenza-like Illness, sponsored by Emergo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT04610047 is a Phase 2 study of Influenza and Influenza-like Illness that has completed, run by Emergo Therapeutics. The registered enrollment target is 315 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04610047, a Phase 2 study of Influenza and Influenza-like Illness, has completed, sponsored by Emergo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Norketotifen
Study Locations (20)
Florida
- Omega Research Debary - DeBary
- The Chappel Group Research - Kissimmee
- South Florida Research Center - Miami
- Premier Research Associate - Miami
- Research Institute of South Florida - Miami
Pennsylvania
- Frontier Clinical Research - Scottdale
- Frontier Clinical Research - Smithfield
Texas
- Cedar Health Research - Dallas
- Advanced Medical Group - Houston
Arizona
- Precision Trials AZ - Phoenix
California
- Downtown LA Research Center - Los Angeles
Louisiana
- Horizon Research Group of Opelousas - Eunice
Maryland
- Continental Clinical Solutions - Towson
Nevada
- Clinical Research of South Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2022-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04610047
The ClinicalTrials.gov registry entry for NCT04610047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is Emergo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04610047 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT04610047 about?
NCT04610047 is a clinical study titled "Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness". This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
What is the current status of trial NCT04610047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2020-12-14. Estimated completion is 2022-02-09.
What conditions does trial NCT04610047 study?
This clinical trial studies the following conditions: Influenza, Influenza-like Illness.
What interventions are being tested in trial NCT04610047?
The interventions under investigation include: Placebo (DRUG), Norketotifen (DRUG).
Who is sponsoring clinical trial NCT04610047?
This trial is sponsored by Emergo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04610047 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.